RecruitingNot ApplicableNCT06285006

Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis

Predictors of Success and Relapse After Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis


Sponsor

Al-Azhar University

Enrollment

50 participants

Start Date

Feb 23, 2024

Study Type

INTERVENTIONAL

Summary

Nocturnal Enuresis (NE) is defined as the involuntary passage of urine during sleep past the age of usual control, which is considered a developmental age of 5 to 7 years. NE is a common problem that causes distress to both children and their families. It has an adverse impact on behavior and social life, affects self-esteem, and can result in poor emotional well-being. In Egypt, the prevalence of NE in primary school children is about 15.4%. The family history was seen to have had a markedly significant impact on the occurrence of NE in the studied children. The mainstay of treatment is urotherapy with information and psychoeducation about normal lower urinary tract function, the underlying cause of MNE, disturbed bladder dysfunction in the child with NMNE, and instructions about therapeutic strategies. Alarm therapy and desmopressin are effective in randomized trials. Children with NMNE first need treatment of the underlying daytime functional bladder problem before treatment of nocturnal enuresis.


Eligibility

Min Age: 7 YearsMax Age: 14 Years

Inclusion Criteria2

  • School age group (from 7 to 14 years)
  • Primary monosymptomatic nocturnal enuresis

Exclusion Criteria7

  • Patients with one or more of the following will be excluded from the study.
  • Diurnal enuresis
  • Urinary tract infection within the preceding 3 months
  • Diabetes mellitus
  • History of renal disease, hypertension or genitourinary abnormality, neurological disease, or psychological disease.
  • Post-micturition residual urine >1/3 expected bladder capacity.
  • Each patient will be subjected to the following.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDesmopressin

Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.


Locations(1)

Alazhar university

Asyut, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06285006